MYC and neoplasm: When combined with anti-PD-L1, a majority of tumors fully regressed and the mice were resistant to further tumor implants at a second site, suggesting that local immunostimulation combined with a systemic checkpoint inhibitor is effective in MYC-driven tumors and can provide durable systemic anti-tumor immunity.